Reem Emad Al-Dhaleai
Research Subjects
Reem Emad Al-Dhaleai has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra E. Butler
Royal College of Surgeons of Ireland, Adliya, Bahrain
2 shared publications - Mustafa Tariq Khan
School of Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen P.O. Box 15503, Bahrain
2 shared publications - Abdulrahman Husain AlSadeq
School of Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen P.O. Box 15503, Bahrain
1 shared publication - Sarah M. Alayadhi
School of Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen P.O. Box 15503, Bahrain
1 shared publication - Zaid Chilmeran
School of Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen P.O. Box 15503, Bahrain
1 shared publication - Zainab Alhalwachi
Department of Postgraduate Studies and Research, Royal College of Surgeons in Ireland, Medical University of Bahrain Busaiteen, Adliya P.O. Box 15503, Bahrain
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by MDPI AG in Biosensors
- Vol. 16 (9) , 507
Artificial Pancreas and Closed-Loop Insulin Delivery: From Early Concepts to AI-Driven Diabetes Automation
Closed-loop insulin delivery, or the artificial pancreas, has evolved from an ambitious engineering concept into one of the most consequential advances in diabetes technology. By integrating continuous glucose monitoring, insulin pumps, and control algorithms into a single feedback system, these platforms aim to shift diabetes care from repeated manual correction toward more anticipatory and adaptive glucose regulation. The field has progressed from early proof-of-concept systems to contemporary hybrid closed-loop platforms, reflecting a deeper shift in diabetes management itself: from treating glucose excursions after they occur to trying to blunt them in real time. Its clinical relevance is greatest in type 1 diabetes, where the burden of self-management is high and the consequences of glycemic instability are immediate. This review introduces the major technologies and evidence shaping the field, with emphasis on the control strategies that drive system behavior, and asks which currently available closed-loop systems offer the best balance of glycemic benefit, usability, and translational readiness for routine diabetes care. Across randomized trials and real-world studies, automated insulin delivery has consistently improved time in range, reduced hypoglycemia, and enhanced patient experience, particularly in pediatric populations. At the same time, important limitations remain: sensor lag, the physiologic constraints of subcutaneous insulin, device complexity, cost, and unequal access limit full autonomy and widespread adoption. Looking ahead, the next phase of progress will likely depend on more adaptive artificial intelligence, improved meal detection, multimodal wearable data, and multi-hormone systems that move the field closer to truly physiologic glucose control.
- 10 September 2026
- Published by MDPI AG in Biosensors
- Vol. 16 (9) , 507
Open AccessArtificial Pancreas and Closed-Loop Insulin Delivery: From Early Concepts to AI-Driven Diabetes Automation
Closed-loop insulin delivery, or the artificial pancreas, has evolved from an ambitious engineering concept into one of the most consequential advances in diabetes technology. By integrating continuous glucose monitoring, insulin pumps, and control algorithms into a single feedback system, these platforms aim to shift diabetes care from repeated manual correction toward more anticipatory and adaptive glucose regulation. The field has progressed from early proof-of-concept systems to contemporary hybrid closed-loop platforms, reflecting a deeper shift in diabetes management itself: from treating glucose excursions after they occur to trying to blunt them in real time. Its clinical relevance is greatest in type 1 diabetes, where the burden of self-management is high and the consequences of glycemic instability are immediate. This review introduces the major technologies and evidence shaping the field, with emphasis on the control strategies that drive system behavior, and asks which currently available closed-loop systems offer the best balance of glycemic benefit, usability, and translational readiness for routine diabetes care. Across randomized trials and real-world studies, automated insulin delivery has consistently improved time in range, reduced hypoglycemia, and enhanced patient experience, particularly in pediatric populations. At the same time, important limitations remain: sensor lag, the physiologic constraints of subcutaneous insulin, device complexity, cost, and unequal access limit full autonomy and widespread adoption. Looking ahead, the next phase of progress will likely depend on more adaptive artificial intelligence, improved meal detection, multimodal wearable data, and multi-hormone systems that move the field closer to truly physiologic glucose control.
- Open Access
- 22 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10264
The Role of Gene Therapy and RNA-Based Therapeutic Strategies in Diabetes
Gene therapy and RNA (ribonucleic acid)-based therapeutic strategies have emerged as promising alternatives to conventional diabetes treatments, significantly expanding the therapeutic landscape using viral and non-viral vectors, and RNA modalities such as mRNA (messenger ribonucleic acid), siRNA (small interfering ribonucleic acid) and miRNA (micro ribonucleic acid). Recent advancements in these fields have led to notable preclinical successes and ongoing clinical trials, yet they are accompanied by debates over safety, efficacy and ethical considerations that underscore the complexity of clinical translation. This review offers a comprehensive analysis of the underlying mechanisms by which these treatments target diabetes, critically evaluating the fundamental concepts and mechanistic insights that form their basis, while highlighting current research gaps, such as the challenges in long-term stability and efficient delivery of RNA-based therapies, and potential adverse effects associated with gene therapy techniques. By synthesizing diverse perspectives and controversies, the review outlines future directions and interdisciplinary approaches aimed at overcoming existing hurdles, ultimately setting the stage for innovative, personalized diabetes management and addressing the broader clinical and regulatory implications of these emerging therapeutic strategies.
- 22 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10264
Open AccessThe Role of Gene Therapy and RNA-Based Therapeutic Strategies in Diabetes
Gene therapy and RNA (ribonucleic acid)-based therapeutic strategies have emerged as promising alternatives to conventional diabetes treatments, significantly expanding the therapeutic landscape using viral and non-viral vectors, and RNA modalities such as mRNA (messenger ribonucleic acid), siRNA (small interfering ribonucleic acid) and miRNA (micro ribonucleic acid). Recent advancements in these fields have led to notable preclinical successes and ongoing clinical trials, yet they are accompanied by debates over safety, efficacy and ethical considerations that underscore the complexity of clinical translation. This review offers a comprehensive analysis of the underlying mechanisms by which these treatments target diabetes, critically evaluating the fundamental concepts and mechanistic insights that form their basis, while highlighting current research gaps, such as the challenges in long-term stability and efficient delivery of RNA-based therapies, and potential adverse effects associated with gene therapy techniques. By synthesizing diverse perspectives and controversies, the review outlines future directions and interdisciplinary approaches aimed at overcoming existing hurdles, ultimately setting the stage for innovative, personalized diabetes management and addressing the broader clinical and regulatory implications of these emerging therapeutic strategies.